301 results about "Phenyl-naphthylene" patented technology

The invention discloses phosphorescent luminescent materials and a preparation method and application thereof. The invention is characterized in that the phosphorescent luminescent materials are red light materials containing a metal iridium complex; a structural general formula of the phosphorescent luminescent materials is shown in the specification; and in the structural general formula, R1 and R2 are independently one of alkyl, phenyl, halogen-substituted phenyl, alkyl-substituted phenyl, naphthyl, anthryl, a halogen substituent, methoxy, phenoxy, cyano-substituted carbazolyl, substituted N-phenylcarbazolyl, quinolyl, thiazolyl, thienyl, an aromatic amino group, a group with an azole structure, an aromatic heterocyclic radical, a substituted aromatic heterocyclic radical and a silicon alkyl substituent respectively. The phosphorescent materials have high luminous efficiency; and the high luminous efficiency shows that the compounds can be taken as luminescent materials or main luminescent materials and applied to electroluminescent devices. Through data test and comparison, the materials are organic electroluminescent materials which have excellent performance and a good prospect, and particularly are phosphorescent red light materials which have good performance; and moreover, a method for synthesizing the luminescent materials is simple and low in cost.

Compounds of the formula I:including any possible stereoisomers thereof, wherein:R1 is hydrogen or halo;R4 is a monophosphate, diphosphate or triphosphate ester; or R4 is a group of formulaR7 is optionally substituted phenyl; naphthyl; indolyl or N—C1-C6alkyloxycarbonyl-indolyl;R8 is hydrogen, C1-C6alkyl, benzyl;R8′ is hydrogen, C1-C6alkyl, benzyl; orR8 and R8′ together with the carbon atom to which they are attached form C3-C7cycloalkyl;R9 is C1-C10alkyl, benzyl, or optionally substituted phenyl;or a pharmaceutically acceptable salt or solvate thereof.pharmaceutical formulations and the use of compounds I as HCV inhibitors.

The use of an additive including a mixture of oligomers that is produced from the reaction of aromatic amines chosen from:(i) the reaction with one another of diphenylamine (DPA) compounds of formula (I) below:wherein the groups R1 and R2 stand for, independently of one another, a hydrogen or a linear or branched alkyl group having from 1 to 30 carbon atoms, advantageously from 4 to 12 carbon atoms,(ii) the reaction with one another of phenyl-α-naphthylamine (PAN) compounds of formula (II) below:wherein the group R3 stands for a hydrogen or a linear or branched alkyl group having from 1 to 30 carbon atoms, advantageously from 4 to 12 carbon atoms, and(iii) the reaction of a (DPA) compound of formula (I) above with a (PAN) compound of formula (II) above as an agent for the stabilization of a lubricating composition for a conveyor chain subjected to a temperature of at least 120° C.

An arginine derivative represented by the formula: [wherein Ar<1 >and Ar<2 >may be the same or different, and are each a phenyl group, a substituted phenyl group, a naphthyl group, a substituted naphthyl group or a heteroaromatic ring group containing one or more of nitrogen, oxygen and sulfur atoms; Y<1 >is a C1-5 alkylene group, a C2-5 alkenylene group or a single bond; and the C1-5 alkylene group optionally contains a carbon atom substituted with a phenyl group, a substituted phenyl group, a naphthyl group, a substituted naphthyl group or a C1-10 acylamino group; Q is a carbonyl group or a sulfonyl group; Y<2 >is a C1-5 alkylene group; the C1-5 alkylene group optionally contains a carbon atom substituted with a phenyl group, a substituted phenyl group, a naphthyl group, a substituted naphthyl group, a hydroxyl group, a carbamoyl group, a mono-C1-5 alkylamide group or a di-C1-5 alkylamide group], or a pharmaceutically acceptable salt thereof. There are provided peptidergic ligands which have the affinity and specificity to MC4 receptor.

The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods ofinhibilion the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as cardiovascular disease, inflammatory disease and autoimmune disease and cell proliferative disorder. Formula (I) Y1 is selected from the group consisting of: (a) and (b); Z is O or S; D1 is selected from the group consisting of: (a) phenyl substituted with a group, R5 (b) naphthyl (c) C3-8cycloalkyl (d) heteroaryl (e) heterocyclyl.

A phenyl-substituted 1,3,5-triazine compound represented by the general formula (1);wherein Ar1 and Ar2 independently represent substituted or unsubstituted phenyl, naphthyl or biphenylyl group; R1, R2 and R3 independently represent hydrogen atom or methyl group; X1 and X2 independently represent substituted or unsubstituted phenylene, naphthylene or pyridylene group; p and q independently represent an integer of 0 to 2; and Ar3 and Ar4 independently represent substituted or unsubstituted pyridyl or phenyl group. This compound is suitable for an organic electroluminescent device.

PCT No. PCT / JP98 / 01225 Sec. 371 Date Sep. 24, 1999 Sec. 102(e) Date Sep. 24, 1999 PCT Filed Mar. 23, 1998 PCT Pub. No. WO98 / 42686 PCT Pub. Date Oct. 1, 1998LDL receptor gene expression promoters containing a 1,2,4-triazine derivative of the formula (I): wherein R1 is optionally substituted phenyl or heterocycle; R2 is optionally substituted phenyl, naphthyl, aralkyl, 5- or 6-membered aromatic heterocycle, alkyl, or alkenyl; X is O, S or NR4; R3 is optionally substituted phenyl, naphthyl, aralkyl, 5- to 6-membered aromatic heterocycle, alkyl, cycloalkyl or alkenyl, provided that when X is NR4, then it may form an optionally substituted nitrogen-containing heterocycle, or a pharmaceutically acceptable salt thereof, which can increase the expression dose (the amount of mRNA) of LDL receptor gene, and thus increase the amount of LDL receptor, and reduce the serum cholesterol level, and are useful in the treatment of hyperlipidemia.

The invention provides a composite amine antioxidant, which at least comprises the following two substances: (1) alkylated diphenylamine and (2) alkylated N-phenyl-alpha-naphthylamine. The composite amine antioxidant is prepared by addition of diisobutylene into mixture of the diphenylamine and the N-phenyl-alpha-naphthylamine for alkylation reaction in the presence of acid catalyst. The composite amine antioxidant provided by the invention has good oil-soluble performance and antioxidation, and can be widely applied to various lubricating oil.

Described herein are antipyschotic compounds of formula (I)wherein,A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S;Alk is (C1-4) alkylene optionally substituted with OH, methoxy, ethoxy, or F;Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic;R1 is hydrogen or (C1-4) alkyl optionally substituted with OH, OR3, or OCH2CH2OH,wherein R3 is (C1-2) alkyl;R2 is H, (C1-6) alkyl, halogen, fluorinated (C1-6) alkyl, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or optionally substituted phenyl,whereinR4 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, or optionally substituted phenyl,R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl;Z is one or two substituents independently selected from hydrogen, halogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2R7, NR8R9, or optionally substituted phenyl,whereinR7 is hydrogen, (C1-6) alkyl, fluorinated alkyl, or optionally substituted phenyl,R8 and R9 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl;and salts, solvates, and crystal forms thereof.Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorder, and pharmaceutical formulations of the compounds of formula (I).

A naphthopyran compound represented by the formulaB1 and B2 are selected from a phenyl, naphthyl, or heterocyclic aromatic group, or may combine to form one or more aromatic rings. B1 and B2 are optionally substituted with one or more substituents. R3, R4, R5, R6, and R10 are selected independently from hydrogen, halogen, —Ra, —OH, —ORa, —O—CO—Ra, —CN, —NO2, —SO2Ra, —SORa, —SH, —SRa, —NH2, —NHRa, —NRaRa, and —NRbRc. Any two or more of R5, R6 or R10 may combine to form a cyclic group. R7 is a mesogenic group containing at least two rings connected to each other through a covalent bond or linking unit. The linking unit is an ester, —Rd—, —O—, —ORd—, —ORdO—, —OCORd—, —OCORdO—, —S—, —CH═CH—, —CH═N—, —C≡C—, or —N═N—, where Rd is a linear or branched (C1-18)alkyl or a linear or branched (C1-18)haloalkyl group. The naphthopyran compound may be incorporated into an optical article.

The invention relates to a phosphorescent compound and an organic light emitting diode device using the same, in particular to a soluble phosphorescent host compound with excellent color purity, highluminance and luminous efficiency and an OLED device using the same. The phosphorescent compound is characterized in that the structural formula is shown as formula I (please see the specification forthe formula), and in the structural formula I, Z is independently selected from the following structures (please see the specification for the formulas), wherein Ar is independently selected from C6-C30 aryl groups and C2-C30 heteroaryl groups, the C6-C30 aryl groups are selected from one of a phenyl group, a naphthyl group, a biphenyl group, a terphenyl group and a phenanthryl group, and the C2-C30 heteroaryl groups are selected from one of a pyridyl group, a bipyridyl group, a quinolyl group, an isoquinolyl group, a phenanthroline group and a triazinyl group. The phosphorescent compound adopts the chemical formula I as a luminous layer of the organic light emitting diode device, and has the excellent color purity and luminance as well as an extended durability effect.

The invention relates to an organic material and an organic electroluminescence device comprising the same. The material has the structural general formula shown in the description, wherein Ar is sub-fused-ring aromatic hydrocarbons with the carbon atoms between 6 and 30, or sub-fused heterocyclic aromatic hydrocarbons with the carbon atoms between 6 and 30; R1 is phenyl, biphenyl, naphthyl, alkyl with 1 to 5 carbon atoms or hydrogen; and n is an integer from 2 to 3. The organic material can be used as an electron transport layer in the organic electroluminescence device.

A novel diarylamine novolac resin such as a phenylnaphthylamine novolac resin, and further a resist underlayer film-forming composition in which the resin is used in a lithography process for manufacturing a semiconductor device. A polymer including a unit structure (A) of Formula (1):(in Formula (1), each of Ar1 and Ar2 is a benzene ring or a naphthalene ring). A method for manufacturing a semiconductor device, including: forming an underlayer film on a semiconductor substrate with the resist underlayer film-forming composition; forming a hardmask on the underlayer film; forming a resist film on the hardmask; forming a resist pattern by irradiation with light or an electron beam followed by development; etching the hardmask with the resist pattern; etching the underlayer film with the hardmask thus patterned; and processing the semiconductor substrate with the underlayer film thus patterned.